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Background: The six-minute walk test (6MWT) is widely used because it is both simple and reliable as a measure of
exercise capacity. Individuals with chronic obstructive pulmonary disease (COPD) usually show a limited capacity to
perform exercise.
Methods: Our study is a prospective, randomized controlled trial which uses the 6MWT in one hundred
consecutive in and out- patients with moderate to severe COPD to assess the benefit of a simple positive expiratory
pressure (PEP) device. PEP device consisted of a PEP valve 5 cmH2O connected to 1-meter tube and a mouthpiece.
All the enrolled patients performed a 6MWT before randomization. The following day PEP group patients
performed the 6MWT using PEP device. Control group patients performed the 6MWT without this device. The
primary outcome was the difference in distance (meters) walked.
Results: Functional capacity assessed by the distance covered during 6MWT improved in the PEP group more than
in the control group. The difference was statistically significant (p < 0.001).Oxygen saturation improved to a
statistically significant level during 6MWT (p < 0.01). Heart rate was also reduced (p < 0.03).
Conclusions: There are few studies demonstrating that PEP devices enhance exercise capacity in COPD patients.
Our results has been obtained using only a low positive expiratory pressure (5 cmH2O). In our opinion the strength
of this study is the simplicity and the lower cost when compared to other devices and approaches. The study was
registered as Chi CTR-ORC-12002173 at www.chictr.org.
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Exercise capacity is the most common measure of car-
diovascular and metabolic efficiency. The six minute
walk test (6MWT) is a standard procedure used to
evaluate exercise capacity in pulmonary and cardiac pa-
tients [1]. Although the cardiopulmonary exercise test
with gas exchange is the “gold standard” method for
measuring exercise in respiratory medicine, its use in
routine clinical practice is limited because it requires* Correspondence: antonello.nicolini@fastwebnet.it
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reproduction in any medium, provided the orexpensive and complex technology. The 6MWT is the
most widely used because it is both simple and reliable
as a measure of exercise capacity.
The 6MWT is internationally used to measure func-
tional status and prognosis in patients with a wide var-
iety of diseases, such as pulmonary hypertension,
congestive heart failure or chronic obstructive pulmon-
ary disease (COPD). It can also be utilized to investigate
the effects of several interventions (rehabilitation,
pharmacological therapy, oxygen supplementation) on
the patients’ walking capacity [2,3]. This test, referred to
as a sub-maximal high-intensity constant-load exercise,
is conducted for a period of 6 minutes while the patientLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patients’ characteristics at baseline
PEP Group n = 50
patients
Control group
n = 50 patients
GENDER F/M 24/50 18/50
AGE years 71.9 ± 4.0 72.1 ± 4.1
FVC% 51.26 ± 11.89 49.67 ± 12.68
FEV1% 35.14 ± 14.56 33.48 ± 10.57
FEV1/FVC% 48.2 ± 8.4 53.2 ± 5.5
TLC% 147.36 ± 44.29 129.44 ± 10.27
RV% 148.82 ± 13.4 140.88 ± .13.22
DLCO% 54.68 ± 11.40 60.03 ± 0.10
paO2 67.1 ± 6.6 61.8 ± 7.0
paCO2 44.7 ± 3,3 43.8 ± 5.0
pH 7.41 ± 0,1 7.42 ± 0,2
DLCO, Lung diffusing capacity for carbon monoxide; FEV1, Forced expiratory
volume 1 sec; FEV1/FVC Tiffeneau index; FVC, Forced vital capacity; PaCO2,
carbon dioxide arterial pressure. PaO2, oxygen arterial pressure; PEP, Positive
Expiratory Pressure;RV, Residual volume; TLC, Total lung capacity.
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http://www.mrmjournal.com/content/8/1/19is walking as far as possible. A supervised measurement
of the distance walked (in meters), with associated pulse
oximetry evaluations, and rating of dyspnea detected
with the Borg scale or with visual analogic scale are then
recorded as outcome measures [3]. In COPD patients
the distance walked correlates moderately with either an
individual’s health-related quality of life, symptoms, peak
work capacity as assessed by CPET or pulmonary func-
tion [2,3]. Most important, the distance walked is a sur-
rogate marker of long-term survival in COPD patients,
even when they are in the most advanced status of their
disease [3].
Many patients with chronic respiratory diseases, par-
ticularly those with COPD present a dysfunction related
to a disorder of the skeletal muscles that reflects a limi-
tation in exercise capacity [3]. COPD is a pulmonary dis-
order that is characterized by progressive irreversible
airflow limitation resulting from alveolar wall destruc-
tion, bronchiolar narrowing, and airways inflammation
[4]. Individuals with COPD usually show a limited cap-
acity to perform exercise. When compared to healthy in-
dividuals they demonstrate lower maximum exercise
capacities with the lowest levels observed in subjects
with more severe COPD [5]. Patients with COPD typic-
ally experience dyspnea during exercise and stop exercis-
ing because of dyspnea or leg fatigue or a combination
of both. Patients with mild COPD usually perceive dys-
pnea more intensely than leg fatigue [6,7]. In this group
the breathing pattern is more rapid and shallow and is
the cause of dynamic hyperinflation which generates an
inspiratory threshold due to positive end-expiratory
pressure which results in a reduction of inspiratory cap-
acity strictly related to dyspnea and in respiratory effort
[7]. Dynamic hyperinflation is the result of expiratory
flow limitation: most people with COPD are able to
maintain a stable end expiratory lung volume (EELV)
and inspiratory capacity (IC) at rest. However, with the
increased ventilatory demand imposed by exercise, the
expiratory flow limitation arise. This leads to increased
EELV and reduced IC.These two parameters have been
identified as major contributory factors to dispnea in
COPD patients [8].Treatments to reduce airflow ob-
struction and/or dynamic hyperinflation include pursed
lip breathing (PLB) [9], several non-pharmacological
therapies that include supplemental oxygen, heliox,
breathing helium-oxygen mixtures, and non-invasive
ventilation [7,9]. There is evidence that non-invasive
ventilation reduces the work of breathing during exer-
cise which in turn decreases dyspnea and increases en-
durance time in patients with moderate to severe
COPD. Several studies have demonstrated a relationship
between decreased dyspnea and reduced work of breath-
ing [7,10-12]. Only few evidences exist concerning the
use of positive expiratory devices: these devices shouldpermit a reduction in lung hyperinflation and an in-
creasing in exercise duration (endurance) [13]. On this
regard we decided to investigate if the use of a positive
expiratory pressure device could improve the distance
walked by patients with moderate to severe COPD.Methods
Patients and study design
A prospective, randomized controlled trial was performed
from April 2012 to September 2012 in consecutive in-and
outpatients with moderate to severe COPD recruited at
the Respiratory Diseases Unit of the General Hospital of
Sestri Levante (GE, Italy). Inclusion criteria were: age from
18 to 80 years, and clinical stability (no change in medica-
tion within a week prior to the test). Exclusion criteria
were: history of bronchial asthma, inability to perform the
six minute walk test, or absence of written consent.
A randomization plan was generated by a statistician not
involved in the study using a randomization table from a
computer software program. The randomization assign-
ments were provided to the recruiting physician in sealed
envelopes. The investigators who performed the study’s
data analysis were blinded to the patients’ assignments.
The study was carried out in accordance with the
Helsinki Declaration. All patients provided written in-
formed consent before beginning the study. The study
was registered as Chi CTR-ORC-12002173 at www.
chictr.org.Protocol
We assessed the effects of a positive expiratory pressure
(PEP) device during 6MWT in patients with moderate
to severe COPD.
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Figure 1 Patients’ flow.
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Figure 2 Positive expiratory pressure (PEP) device used for 6
MWT composed by a 5 cm H2O Respironics PEP-valve,a tube
and a mouthpiece.
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randomized (37 were excluded: 27 refused informed
consent and 10 were unable to perform 6MWT). The
demographic and baseline characteristics of the enrolled
patients are reported in Table 1. The patients’ flow chart
is reported in Figure 1. Pulmonary function testing was
performed with a computerized body plethysmograph
(VMAX 20 PFT Sensor Medics, Yorba Linda, CA,US),
according to the international standards [14].Figure 3 A participant using PEP device before 6 MWT.Each patient underwent 6MWT in the first day, the
test was performed twice to avoid learning effect [15];
the test of the two (performed the same day and sepa-
rated each other by at least 30 minutes) with the longest
covered distance was inserted in data analysis [15-17].
The following day the subjects were randomized to the
PEP arm (50 patients) or to the Control arm (50 pa-
tients). PEP group patients repeated 6MWT only once
using a PEP device consisting in a Respironics Threshold
PEP valve set at 5cmH2O [18] connected to a 20 mm
inner diameter and 100 mm tube and a mouthpiece
(Figures 2 and 3) [19]. Control group patients repeated
6MWT only once breathing without this device. A dif-
ferent chest physiotherapist performed the 6MWT and
he/she was blinded about the results of the previous test.
6MWT was performed according to the American Thor-
acic Society guidelines [20].
Oxygen saturation, heart rate, respiratory rate, dyspnea
(using the Borg scale), and distance walked (meters)
were recorded at the beginning and the end of every test
as previously indicated [13]. A lightweight bluetooth
wireless oxymeterNonin Avant 4000 was used for con-
tinuous oxygen saturation and heart rate measurements.
Data analysis and statistics
Primary outcome was the difference in distance (meters)
walked between the test before enrollment and the test
after enrollment. Secondary outcomes were the differ-
ences in oxygen saturation, the reduction in dyspnea
(Borg scale), and in respiratory rate. Descriptive data for
continuous variables with a normal distribution are
presented as mean ± standard deviation. Covariance
analysis was used for assessing the difference between
6MWT with or without PEP. Multivariate analysis was
used to evaluate correlations between cardio-pulmonary
function parameters and patient performance. The ef-
fects of possible confounding factors (sex, age, metersFigure 4 Trend analysis of distance (T0–T1) (meters walked) in
the PEP group and in the Control group (p < 0.001).
Table 2 Results of parameters evaluated before and after 6MWT in the two groups of patients (PEP group–Control
group)
6MWT 1stTEST 6MWT 2ndTEST
(before randomization) (after randomization)
Group A (PEP) Group B Group A (PEP) Group B p
Distance walked (meters)
232.56 ± 101.59 262.44 ± 95.02 294.22 ± 97.31 265.67 ± 94.43 < 0.02
Dyspnea (Borg)
Time 0* 1.63 ± 1.20 1.08 ± 1.03 1.49 ± 0.90 0.86 ± 0.97 0.4339
Time 1** 4.29 ± 1.75 4.22 ± 2.01 3.18 ± 1.65 4.41 ± 2.14
Respiratory rate
Time 0* 19.92 ± 5.26 20.68 ± 4.80 19.62 ± 4.64 20.65 ± 4.45 0.4884
Time 1** 26.68 ± 4.04 27.08 ± 4.35 23.38 ± 5.09 27.22 ± 3.28
Heart rate
Time 0* 80.17 ± 14.70 78.75 ± 10.23 80.17 ± 12.72 76.67 ± 13.48 <0.03
Time 1** 96.66 ± 15.76 97.36 ± 11.71 92.56 ± 12.57 98.96 ± 13.86
Oxygen saturation %
Time 0* 94.74 ± 0.01 94.61 ± 0.01 94.96 ± 0.02 94.84 ± 0.01 <0.01
Time 1** 88.97 ± 0.04 90.27 ± 0.04 90.75 ± 0.03 89.76 ± 0.04
* At the beginning of the test.
** At the end of the test.
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these variables in the final model and calculating the
change in the predictive factors coefficients.
Data analysis was done with statistics software R-Project
version 7.13.2. A significance level of p < 0.05 was used for
all comparisons.Results
All one hundred patients concluded the study. There
were twenty-four females in the PEP group and eighteen
in the control group. The average age of the participants
was 71.9 ± 4.0 in the PEP group and 72.1 ± 4.1 in control
group. 36 patients of the PEP group were being treated
with association of inhaled β2 agonist plus corticosteroid
and tiotropium bromide; the remaining 14 with β2 agon-
ist and tiotropium. 39 patients of the PEP group were
being treated with association of β2 agonist plus cortico-
steroid and tiotropium bromide; the remaining 11 with
β2 agonist and tiotropium bromide. 3 patients of the
PEP group and 4 patients of the control group had
chronic respiratory insufficiency treated with oxygen.
All patients had similar reduction in lung volumes
(FVC % 51.26 ± 11.89 in PEP group and 49.67 ± 12.68 in
control group, FEV1% 35.14 ± 14.56 in PEP group and
33.48 ± 10.57 in control group). The 6MWT at baseline
was 232.56 ± 101.59 in PEP group and 262.44 ± 95.02 in
control group.Primary outcomes
Functional capacity assessed by the distance covered dur-
ing 6 MWT improved in PEP group more than in the con-
trol group. The PEP group showed an increase in meters
walked (61.66 ± 4.28) versus Control group (3.23 ± 0.59).
The difference was statistically significant (p < 0.001). The
mean values of distances walked and p-values are reported
in Figure 4.Secondary outcomes
Oxygen saturation improved to a statistically significant
level during 6 MWT (p < 0.01). Heart rate was reduced
(p < 0.03). Also dyspnea (Borg scale) and the respiratory
rate showed a reduction in the PEP group, but these did
not achieve statistical significance. All results are showed
in Table 2. The patients showing ability to maintain an
adequate level of saturation improved the distance
walked (multivariate analysis) (p < 0.03).Discussion
The present study suggests that adding a low positive pres-
sure (5 cmH2O) PEP device enhances exercise capacity
expressed as distance walked during 6MWT in patients
with moderate to severe COPD. The principal effect of PEP
device consists in increasing expiratory flow and decreasing
pulmonary hyperinflation during exercise.
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physiological hallmark of chronic obstructive, is caused
by reduced lung elastic recoil and increased airway
resistance. Forced expiration associated with increased
ventilatory demands during exercise can induce prema-
ture airway closure leading to air trapping and dynamic
hyperinflation [13]. Dynamic hyperinflation contributes
to increased elastic and mechanical loads on the inspira-
tory muscles and to neuroventilatory dissociation which
further exacerbate the shortness of breath, leading to ex-
ercise intolerance, limited physical activity and thus to a
poor quality of life [21]. Exercise tolerance is an import-
ant outcome measure in patients with COPD, because
there is evidence that exercise testing is superior to
other functional measurements obtained at rest in dem-
onstrating the positive effect of a specific intervention.
Some drugs such as formoterol and tiotropium demon-
strate ability to change exercise tolerance and 6 MWT
[22,23]. Non-invasive ventilation was used to improve
exercise tolerance in COPD patients [24-27]. One of the
various explored strategies to manage dynamic hyperin-
flation is to increase expiratory time as a result of
slowing the respiratory rate by using low-level positive
expiratory pressure [28]. Positive expiratory pressure de-
vices can prolong expiratory time and decrease respira-
tory rate, thereby reducing airway closure and dynamic
hyperinflation. The use of an expiratory positive airway
pressure (associated with incentive spirometry) was de-
scribed in a study in patients after coronary artery by-
pass graft. The application of a positive expiratory
pressure improved the distance walked in 6MWT com-
pared to controls [29]. The expiratory positive expiratory
positive airway pressure promotes collateral ventilation,
prevents airway collapse during expiration and thus re-
duces air trapping [29,30].
Another study about the use of an expiratory positive
pressure device in COPD patients showed that the use
of a conical-PEP produced an increase in inspiratory
capacity of 200 ml, slowdown in vital capacity, and lung
hyperinflation, and the improvement of the exercise en-
durance [13]. Martin and Davenport in a double blind
crossover study showed that an extrinsic 10 cmH2O
threshold PEEP reduced post-exercises dyspnea in
COPD patients [9]. Finally, Monteiro and others pub-
lished in 2012 a study similar to the our in which the
demonstrated an increase in inspiratory capacity in
patients with moderate to severe COPD treated with
PEP applied trough oronasal mask after submaximal
treadmill exercise [31].
However our study presents an important limitation: we
did not measure the dynamic hyperinflation, and this is an
important lack because a strict correlation exists between
exercise dynamic hyperinflation, inspiratory capacity, dys-
pnea and exercise performance during 6MWT [32].Conclusions
Activity in COPD patients is limited by the development of
dynamic hyperinflation. Changes in respiratory mechanics
during exercise in patients with dynamic hyperinflation
lead to exercise intolerance. The use of PEP during
submaximal exercise may promote a reduction in the de-
velopment of dynamic hyperinflation in COPD patients
[31]. Our results has been obtained using only a low posi-
tive expiratory pressure (5 cm H2O) (the same obtained by
pursed lips breathing) [13,18] without an inspiratory sup-
port or an inspiratory incentive device. In our opinion the
strength of our study is the simplicity and the minor cost
when compared to other devices and approaches (such as
non-invasive ventilation or incentive spirometry with ex-
piratory positive airway pressure or even conical-PEP). The
use of PEP devices in rehabilitation programs is well
known [9]: future studies would be needed to verify the
usefulness of this device in the usual way (daily activity)
during training and reconditioning.
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